Topic: checkpoint inhibitors
Merck just pulled off a coverage feat that its immuno-oncology rivals haven’t so far.
Less than eight months after nabbing a 50% share of hot AstraZeneca drug Lynparza, Merck is back with another partnership—this time on Eisai’s Lenvima.
BMS has longevity and strong data on its side when it comes to staying on top of the immuno-oncology field. But a convenience boost can’t hurt.
After two recent trial flops, Pfizer and Merck KGaA are getting some good news around immuno-oncology contender Bavencio.
BN's cancer vaccine CV301 is already under evaluation with Keytruda in NSCLC and with Tecentriq in bladder cancer.
Backed by convincing survival data, AZ’s fifth-to-market immunotherapy Imfinzi just won a breakout FDA approval in certain lung cancer patients.
Pfizer and Merck KGaA have suffered another setback with immuno-oncology med Bavencio—and this one’s raising some eyebrows.
Kidney cancer isn’t the only disease area where Merck’s Keytruda is moving in to challenge Bristol-Myers Squibb’s Opdivo.
Investors worried last year that Merck couldn’t replicate its Keytruda-chemo combo success in a phase 3 trial. But it just did.
BMS’s Opdivo is the only immuno-oncology drug approved to treat kidney cancer, but more rivals are threatening that status.